Table 2.
Patients with surgically treated SM stratified for synchronous vs. metachronous SM occurrence
| Synchronous diagnosis of SM n = 97 |
Metachronous diagnosis of SM n = 114 |
p value | |
|---|---|---|---|
| Median age (yrs) | 67 (58–73) | 65 (57–75) | 0.8 |
| Female sex | 46 (47) | 35 (31) | 0.02 |
| Pre-operative KPS < 70 | 27 (28) | 43 (38) | 0.1 |
| Primary tumor site | |||
| Lung | 34 (35) | 15 (4) | <0.001 |
| Breast | 20 (21) | 4 (4) | <0.001 |
| Prostate | 14 (14) | 32 (28) | 0.019 |
| Other | 29 (30) | 63 (55) | <0.001 |
| Location of disease | |||
| Cervical | 12 (12) | 9 (8) | 0.4 |
| Thoracic | 50 (52) | 68 (60) | 0.28 |
| Lumbar | 15 (15) | 21 (18) | 0.35 |
| Combined | 20 (21) | 16 (14) | 0.27 |
| Levels of disease | 0.2 | ||
| 1–2 | 53 (55) | 73 (64) | |
| ≥3 | 44 (45) | 41 (36) | |
| Median CCI (IQR) | 8 (7–10) | 8 (6–10) | 0.7 |
| Preoperative neurological deficit (ASIA A-C) | 33 (34) | 33 (29) | 0.5 |
| Surgery | 0.05 | ||
| Decompression | 31 (32) | 50 (44) | |
| Stabilization | 66 (68) | 64 (56) | |
| 1-year mortality | 50/93* (54) | 60/107** (56) | 0.78 |
| Median OS (95% CI) | 13.5 (6.1–15.8) | 13.0 (7.7–14.2) | 0.74 |
Values represent the number of patients unless indicated otherwise (%)
The values in bold are statistically significant
CCI Charlson Comorbidity Index, IQR interquartile range, OS overall survival, SM spinal metastasis, yrs years
* 4 of 97 patients censored with lost to follow-up <12 months
** Median (IQR). 7 of 114 patients censored with lost to follow-up <12 months